参仙升脉口服液治疗窦性心动过缓82例临床分析

Clinical Analysis of Shenxian Shengmai Oral Solution(参仙升脉口服液)in Treatment of 82 Cases of Sinus Bradycardia

目的探究参仙升脉口服液治疗窦性心动过缓82例临床分析。方法对医院2018年2月—2019年2月收治的82例窦性心动过缓患者展开对照研究,将其分为观察组(参仙升脉口服液治疗)与对照组(阿托品治疗)各41例,分组方法为随机数字表法,探讨实施不同治疗对治疗效果的影响。结果研究对象在总有效率上进行对比,观察组97.56%(40/41)显著比对照组82.93%(34/41)高(P<0.05),治疗前研究对象的最快心率、最慢心率、平均心率无显著性差异(P>0.05),治疗后观察组在最快心率、最慢心率、平均心率上显著比对照组高(P<0.05),观察组在舒张早期充盈峰速度(E峰)、E/A比值、左心室舒张末期直径(LVEDD)、射血分数(LVEF)上显著比对照组高(P<0.05),而在A峰上显著比对照组低(P<0.05),研究对象在不良反应发生率上进行对比,观察组4.88%(2/41)显著比对照组21.95%(9/41)低(P<0.05),治疗前,研究对象生活质量各维度评分差异不显著(P>0.05);治疗后,观察组生活质量各维度评分比对照组更高(P<0.05)。结论将参仙升脉口服液治疗应用于窦性心动过缓患者后,可显著提升疗效及生活质量,改善临床症状,减少不良反应,此方法值得应用与推广。

Objective To analyze the effect of Shenxian Shengmai Oral Solution(参仙升脉口服液)on 82 cases of sinus bradycardia.Methods Eighty-two sinus bradycardia patients treated from February 2018 to February 2019 in the hospital were selected and randomly assigned to the observation group(41 cases)and control group(41 cases).The observation group took Shenxian Shengmai Oral Solution.The control group took Atropine.The therapeutic effect was observed.Results The total effective rate in the observation group(97.56%)was significantly higher than that of the control group(82.93%)(P<0.05).Before treatment,the maximal heart rate,minimal heart rate and mean heart rate between two groups were not significantly different(P>0.05).After treatment,the maximal heart rate,minimal heart rate and mean heart rate in the observation group were significantly larger than those of the control group(P<0.05).The mitral valve relaxation early phase peak speed(E peak),E/A,the values of left ventricular end-diastolic diameter(LVEDD)and left ventricular ejection fraction(LVEF)in the observation group were significantly higher than those of the control group(P<0.05).A peak value in the observation group was lower than that of the control group(P<0.05).The adverse event rate in the observation group(4.88%)was lower than that(21.95%)of the control group(P<0.05).Before treatment,the scores of quality of life between two groups were not significantly different(P>0.05).After treatment,the score of quality of life in the observation group was higher than that of the control group(P<0.05).Conclusion Shenxian Shengmai Oral Solution can remarkably reduce the adverse reactions,and improve the quality of life and clinical symptoms.It is worthy of clinical application and promotion.